Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5959
    +0.0023 (+0.38%)
     

  • NZD/EUR

    0.5553
    +0.0007 (+0.13%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.64
    -0.17 (-0.21%)
     

  • GOLD

    2,338.30
    -0.10 (-0.00%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,089.06
    +48.68 (+0.61%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,983.08
    -105.62 (-0.58%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • NZD/JPY

    92.7130
    +0.5980 (+0.65%)
     

Verona Pharma to Present at Jefferies Healthcare Conference

Verona Pharma plc
·1-min read
Verona Pharma plc
Verona Pharma plc

LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 PM ET / 6:30 PM BST.

A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on respiratory diseases. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Top-line data are expected in the third quarter of 2022 and around the end of 2022.

ADVERTISEMENT

If successfully developed and approved, ensifentrine has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

For further information please contact:

Verona Pharma plc

US Tel: +1-833-417-0262
UK Tel: +44 (0)203 283 4200

Victoria Stewart, Director of Investor Relations and Communications

info@veronapharma.com

 

 

Argot Partners
(US Investor Enquiries)

Tel: +1-212-600-1902
verona@argotpartners.com

Kimberly Minarovich / Michael Barron

 

 

 

Optimum Strategic Communications
(International Media and European Investor Enquiries)

Tel: +44 (0)203 950 9144
verona@optimumcomms.com

Mary Clark / Rebecca Noonan / Zoe Bolt